Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke
Authors:
Open Access
- 27 October 2011
- journal article
- research article
- Published by Springer Nature in Translational Stroke Research
- Vol. 3 (1) , 154-163
Abstract
Platelet-activating factor (PAF) accumulates during cerebral ischemia, and inhibition of this process plays a critical role in neuronal survival. Recently, we demonstrated that LAU-0901, a novel PAF receptor antagonist, is neuroprotective in experimental stroke. We used magnetic resonance imaging in conjunction with behavior and immunohistopathology to expand our understanding of this novel therapeutic approach. Sprague–Dawley rats received 2 h middle cerebral artery occlusion (MCAo) and were treated with LAU-0901 (60 mg/kg) or vehicle 2 h from MCAo onset. Behavioral function, T2-weighted imaging (T2WI), and apparent diffusion coefficients were performed on days 1, 3, and 7 after MCAo. Infarct volume and number of GFAP, ED-1, and NeuN-positive cells were conducted on day 7. Behavioral deficit was significantly improved by LAU-0901 treatment compared to vehicle on days 1, 3, and 7. Total lesion volumes computed from T2WI were significantly reduced by LAU-0901 on days 1, 3, and 7 (by 83%, 90%, and 96%, respectively), which was consistent with decreased edema formation. Histopathology revealed that LAU-0901 treatment resulted in significant reduction of cortical and subcortical infarct volumes, attenuated microglial infiltration, and promoted astrocytic and neuronal survival. These findings suggest LAU-0901 is a promising neuroprotectant and provide the basis for future therapeutics in patients suffering ischemic stroke.Keywords
This publication has 32 references indexed in Scilit:
- On the importance of long-term functional assessment after stroke to improve translation from bench to bedsideExperimental & Translational Stroke Medicine, 2011
- Astrocytes: biology and pathologyActa Neuropathologica, 2009
- LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the ratBrain Research, 2009
- A Novel Platelet Activating Factor Receptor Antagonist Reduces Cell Infiltration and Expression of Inflammatory Mediators in Mice Exposed to Desiccating Conditions after PRKJournal of Immunology Research, 2009
- Synergism in the repression of COX-2- and TNFα-induction in platelet activating factor-stressed human neural cellsNeuroscience Letters, 2007
- Behavioral tests for preclinical intervention assessmentNeuroRX, 2006
- Synergistic Effect of Platelet-Activating Factor and Tumor Necrosis Factor-α on Corneal Myofibroblast ApoptosisInvestigative Ophthalmology & Visual Science, 2006
- Middle Cerebral Artery Occlusion in the Rat by Intraluminal SutureStroke, 1996
- Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: Inhibition of ischemia-reperfusion induced cerebral injuryBiochemical and Biophysical Research Communications, 1987
- Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retinaBiochemical and Biophysical Research Communications, 1984